A Retrospective Audit of Selective Serotonin Re-Uptake Inhibitors (Fluoxetine and Paroxetine) for the Treatment of Depressive Episodes in Adults with Learning Disabilities

Bhaumik, Sabyasachi; Branford, David; Naik, Bhiken I.; Biswas, Amitava

doi:10.1179/096979500799155694

Cited by 5 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a retrospective case-note analysis examining the ef®cacy of the SSRIs,¯uoxetine and paroxetine used in the treatment of depression in adults with learning disabilities, Bhaumik et al (2000) reported discontinuation of the SSRI used in 31% (46 treatment episodes) due to intolerable treatmentemergent symptoms. The implications of misdiagnosis, delayed recognition and misinterpretation of these treatment emergent symptoms is too serious to be ignored.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment‐emergent behavioural side effects with selective serotonin re‐uptake inhibitors in adults with learning disabilities

Biswas

Bhaumik

Branford³

2001

Human Psychopharmacology

Self Cite

View full text Add to dashboard Cite

Selective serotonin re-uptake inhibitors are widely used for the treatment of depression suffered by adults with learning disabilities. However, the presentation, time of onset and prevalence of treatment emergent symptoms, have not been extensively studied in adults with learning disabilities. The aim of this study was to determine these aspects of treatment. The study design involved retrospective analysis of case notes of all adults with learning disabilities treated with either fluoxetine or paroxetine for depression. During 31% of treatment episodes, patients suffered treatment emergent symptoms during treatment with either selective serotonin re-uptake inhibitor (SSRI). These symptoms subsided on discontinuation of the SSRI. The common emergent symptoms in this group were elevated mood (39%), decreased sleep (35%), hyperactivity (30%), overtalkativeness (26%), agitation (24%) and aggression (37%). In 20% symptoms developed within 1 month and in 67% within 7 months of starting treatment with a SSRI. There were no significant differences noted in the frequency and nature of treatment emergent symptoms between fluoxetine and paroxetine. Few guidelines, if any, exist for initiating and continuing antidepressant treatment for therapeutic or prophylactic use in this patient population. Close monitoring of efficacy and tolerability, including treatment emergent psychiatric symptoms is warranted. Copyright 2001 John Wiley & Sons, Ltd.

show abstract

Section: Introductionmentioning

confidence: 99%

“…To further this aim, a naturalistic study design was devised to investigate the occurrence of treatment emergent symptoms, resulting in the discontinuation of either SSRI as noted in the above-mentioned study sample (Bhaumik et al, 2000).…”

Section: Introductionmentioning

confidence: 99%

Treatment‐emergent behavioural side effects with selective serotonin re‐uptake inhibitors in adults with learning disabilities

Biswas

Bhaumik

Branford³

2001

Human Psychopharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

Depression in Aging Individuals with Intellectual Disabilities

Davidson¹,

Janicki²

2003

Mental Health, Intellectual Disabilities, and the Aging Process

View full text Add to dashboard Cite

Current awareness in human psychopharmacology

2001

Human Psychopharmacology

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of human psychopharmacology. Each bibliography is divided into 18 sections: 1 Books, Reviews & Symposia; 2 General; 3 Psychotropic Drugs ‐ General; Antidepressive Agents: 4 Tricyclics; 5 Monoamine Oxidase Inhibitors; 6 Serotonergics; Euthymic Agents: 7 Lithium; Tranquillizing Agents: 8 Major; 9 Minor & Hypnotics; 10 Analeptic Agents; 11 Anticonvulsant Agents; 12 Drugs of Abuse; 13 Transmitters, Receptors, Metabolites & Modulating Agents; 14 Neuropeptides; 15 Psychoneuroendocrinology; 16 Psychoneuroimmunology; 17 Behavioural Genetics; 18 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

A Retrospective Audit of Selective Serotonin Re-Uptake Inhibitors (Fluoxetine and Paroxetine) for the Treatment of Depressive Episodes in Adults with Learning Disabilities

Cited by 5 publications

References 3 publications

Treatment‐emergent behavioural side effects with selective serotonin re‐uptake inhibitors in adults with learning disabilities

Treatment‐emergent behavioural side effects with selective serotonin re‐uptake inhibitors in adults with learning disabilities

Depression in Aging Individuals with Intellectual Disabilities

Current awareness in human psychopharmacology

Contact Info

Product

Resources

About